Tenofovir disoproxil/emtricitabine/efavirenz — Competitive Intelligence Brief

Tenofovir disoproxil/emtricitabine/efavirenz (Tenofovir disoproxil/emtricitabine/efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Tenofovir disoproxil/emtricitabine/efavirenz (Tenofovir disoproxil/emtricitabine/efavirenz) — Sheba Medical Center. This combination inhibits HIV reverse transcriptase and integrase through three antiretroviral agents working synergistically to block viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir disoproxil/emtricitabine/efavirenz TARGET	Tenofovir disoproxil/emtricitabine/efavirenz	Sheba Medical Center	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Abacavir/lamivudine and efavirenz	Abacavir/lamivudine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
B/FTC/TAF	B/FTC/TAF	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

1. GlaxoSmithKline · 2 drugs in this class
2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
3. Hospital Clinic of Barcelona · 1 drug in this class
4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
6. Peking Union Medical College Hospital · 1 drug in this class
7. Sheba Medical Center · 1 drug in this class
8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
9. University of KwaZulu · 1 drug in this class